Drug Profile
Research programme: natural killer cell based therapies - Sorrento/Karolinska Institutet
Alternative Names: NK based therapies - Sorrento/ Karolinska InstitutetLatest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Karolinska Institute
- Developer Karolinska Institute; Sorrento Therapeutics
- Class Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer